FDA Clocks In Patent Extension Time for SKYCLARYS Drug
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for SKYCLARYS, a new medicine, so its patent can be extended. This means the company behind SKYCLARYS gets more time to protect their invention before others can copy it. If you’re in the drug business or follow patents, this update affects when the patent extension starts and could impact market timing and profits.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Review Period for SKYCLARYS
The Food and Drug Administration (FDA) determined the regulatory review period for the drug SKYCLARYS and published a notice of that determination. That determination is tied to an application to the U.S. Patent and Trademark Office (USPTO) to extend a patent that claims this human drug product, which can give the patent holder more time to keep competitors from marketing the same drug.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-08247, Proposed Flood Hazard Determinations
FEMA is asking communities and residents to review and comment on new flood risk maps that might change flood zones or water levels. These updates could affect flood insurance rules and costs, so it’s important for those in the listed areas to pay attention and respond by the deadline. Getting these maps right helps keep everyone safer and insurance fair.
Next: 2025-08254, Determination of Regulatory Review Period for Purposes of Patent Extension; JAYPIRCA
The FDA has officially set the review period for JAYPIRCA, a human drug product, so its patent can be extended. This means the company behind JAYPIRCA gets more time to protect their invention and potentially earn more money. Anyone interested in drug patents or new medicines should keep an eye on this important timing update.